NRX Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q4 2017 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: NRX Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q4 2017 to Q3 2024.
NRX Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.02M, a 48% increase year-over-year.
NRX Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$20.5M, a 38.5% increase year-over-year.
NRX Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$27.8M, a 37.2% increase from 2022.
NRX Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$44.3M, a 61.7% increase from 2021.
NRX Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$116M, a 125% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$20.5M	-$3.02M	+$2.79M	+48%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-14
Q2 2024	-$23.3M	-$7.05M	+$1.14M	+13.9%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-14
Q1 2024	-$24.4M	-$6M	+$3.44M	+36.4%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-14
Q4 2023	-$27.8M	-$4.41M	+$5.48M	+55.4%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-29
Q3 2023	-$33.3M	-$5.81M	+$3.33M	+36.5%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-14
Q2 2023	-$36.7M	-$8.19M	+$1.41M	+14.7%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-14
Q1 2023	-$38.1M	-$9.44M	+$6.27M	+39.9%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-14
Q4 2022	-$44.3M	-$9.89M	+$43.1M	+81.3%	Oct 1, 2022	Dec 31, 2022	10-K	2024-03-29
Q3 2022	-$87.4M	-$9.14M	+$11M	+54.5%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-14
Q2 2022	-$98.4M	-$9.6M	+$7.52M	+43.9%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-14
Q1 2022	-$106M	-$15.7M	+$9.9M	+38.7%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-15
Q4 2021	-$116M	-$53M	-$6.75M	-14.6%	Oct 1, 2021	Dec 31, 2021	10-K	2023-03-31
Q3 2021	-$109M	-$20.1M	-$14.9M	-290%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-14
Q2 2021	-$94.1M	-$17.1M	-$17.2M	-16430%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-15
Q1 2021	-$76.9M	-$25.6M	-$25.5M	-21363%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-16
Q4 2020	-$51.4M	-$46.2M	-$46M	-24106%	Oct 1, 2020	Dec 31, 2020	10-K	2022-03-31
Q3 2020	-$5.35M	-$5.15M	-$4.97M	-2709%	Jul 1, 2020	Sep 30, 2020	10-Q/A	2022-08-12
Q2 2020	-$389K	$105K	+$281K		Apr 1, 2020	Jun 30, 2020	10-Q/A	2022-08-12
Q1 2020	-$669K	-$119K	+$43.9K	+26.9%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-21
Q4 2019	-$713K	-$191K	+$131K	+40.7%	Oct 1, 2019	Dec 31, 2019	10-K/A	2021-05-14
Q3 2019	-$844K	-$183K	+$36.9K	+16.8%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-16
Q2 2019	-$881K	-$176K	+$96.1K	+35.3%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-14
Q1 2019	-$977K	-$163K	+$29.2K	+15.2%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-15
Q4 2018	-$1.01M	-$322K	-$188K	-140%	Oct 1, 2018	Dec 31, 2018	10-K	2020-03-30
Q3 2018	-$819K	-$220K			Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-14
Q2 2018		-$272K			Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-14
Q1 2018		-$192K			Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-15
Q4 2017		-$134K			Sep 18, 2017	Dec 31, 2017	10-K	2019-03-15

* An asterisk sign (*) next to the value indicates that the value is likely invalid.